Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection-an observational cohort study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43920758" target="_blank" >RIV/00216208:11120/21:43920758 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064211:_____/21:W0000028 RIV/00064203:_____/21:10417596 RIV/00216208:11130/21:10417596

Výsledek na webu

<a href="https://doi.org/10.1016/j.ijid.2020.11.004" target="_blank" >https://doi.org/10.1016/j.ijid.2020.11.004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijid.2020.11.004" target="_blank" >10.1016/j.ijid.2020.11.004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection-an observational cohort study

Popis výsledku v původním jazyce

PURPOSE: We aimed to evaluate the efficacy of different antibiotic regimens for the treatment of Clostridioides difficile infection (CDI) with regard to the CDI episode number and disease severity. METHODS: An observation cohort study included 271 CDI patients hospitalised between 2013-2016. Univariate logistic regression was used to evaluate the association between patients&apos; clinical outcome (sustained clinical cure or recurrence) in a 60-day follow-up and the antibiotic regimen used (oral metronidazole, oral vancomycin, combination of oral vancomycin and metronidazole, oral fidaxomicin). Subgroup analyses, based on CDI episode number and severity of CDI, were performed. RESULTS: In the overall population, fidaxomicin was superior to metronidazole, vancomycin or their combination for a sustained clinical response and in the prevention of recurrent CDI (rCDI). In the subgroup analyses, fidaxomicin was superior to vancomycin or metronidazole for the initial CDI episode, first CDI recurrence and non-severe CDI for a sustained clinical response and in the prevention of rCDI. In the oral treatment of severe CDI, fidaxomicin had a similar treatment outcome to vancomycin and none of the antibiotic treatments was superior in the prevention of rCDI. Fidaxomicin, vancomycin or a combination of metronidazole and vancomycin had similar outcomes in patients with multiple rCDI for a sustained clinical response and in the prevention of rCDI. CONCLUSION: Fidaxomicin was superior to metronidazole or vancomycin for treatment of the initial episode, first recurrence and non-severe CDI.

Název v anglickém jazyce

Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection-an observational cohort study

Popis výsledku anglicky

PURPOSE: We aimed to evaluate the efficacy of different antibiotic regimens for the treatment of Clostridioides difficile infection (CDI) with regard to the CDI episode number and disease severity. METHODS: An observation cohort study included 271 CDI patients hospitalised between 2013-2016. Univariate logistic regression was used to evaluate the association between patients&apos; clinical outcome (sustained clinical cure or recurrence) in a 60-day follow-up and the antibiotic regimen used (oral metronidazole, oral vancomycin, combination of oral vancomycin and metronidazole, oral fidaxomicin). Subgroup analyses, based on CDI episode number and severity of CDI, were performed. RESULTS: In the overall population, fidaxomicin was superior to metronidazole, vancomycin or their combination for a sustained clinical response and in the prevention of recurrent CDI (rCDI). In the subgroup analyses, fidaxomicin was superior to vancomycin or metronidazole for the initial CDI episode, first CDI recurrence and non-severe CDI for a sustained clinical response and in the prevention of rCDI. In the oral treatment of severe CDI, fidaxomicin had a similar treatment outcome to vancomycin and none of the antibiotic treatments was superior in the prevention of rCDI. Fidaxomicin, vancomycin or a combination of metronidazole and vancomycin had similar outcomes in patients with multiple rCDI for a sustained clinical response and in the prevention of rCDI. CONCLUSION: Fidaxomicin was superior to metronidazole or vancomycin for treatment of the initial episode, first recurrence and non-severe CDI.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Infectious Diseases

ISSN

1201-9712

e-ISSN

—

Svazek periodika

103

Číslo periodika v rámci svazku

February

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

226-233

Kód UT WoS článku

000616676100042

EID výsledku v databázi Scopus

2-s2.0-85098205027